<DOC>
	<DOCNO>NCT00658749</DOCNO>
	<brief_summary>This phase one study evaluate safety , tolerability , bioavailability nebulized AIR645 .</brief_summary>
	<brief_title>A Phase 1 Study AIR645 Healthy Subjects Subjects With Controlled Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion Criteria* : Good General Health ( without allergic rhinitis and/or control asthma ) Nonsmoker least 2 year Normal lung function ( DLCO ) Able provide inform consent understand comply requirement study Exclusion Criteria* : Clinically significant medical history condition precludes participation Clinically significant ECG abnormality Clinically significant VS PE abnormality Clinically significant screening lab abnormality Abnormal lung function ( FEV1 &lt; 80 % predict ) Respiratory infection within 14 day randomization HBV , HCV , HIV Breastfeeding pregnant female History alcohol abuse illicit drug use within past 24 month Use tobacco nicotinecontaining product within past 6 month Use herbal supplement , overthecounter drug , prescription drug allow per protocol Use investigational drug within past 30 day Use investigational monoclonal antibody recombinant protein within past 90 day Donation plasma within past 7 day Donation loss whole blood within past 56 day Simplified list I/E criterion ; unabridged list available upon request .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>AIR645</keyword>
	<keyword>Altair Therapeutics</keyword>
	<keyword>IL4</keyword>
	<keyword>IL13</keyword>
	<keyword>IL-4</keyword>
	<keyword>IL-13</keyword>
</DOC>